April 1, 2022
Menopause publishes cBHT meta-analysis
A paper co-authored by APC board member A.J. Day, “Safety and efficacy of compounded bioidentical hormone therapy (cBHT) in perimenopausal and postmenopausal women” was published Thursday in Menopause: Journal of The North American Menopause Society.
Although limited in scope, its unambiguous conclusion: There is no evidence that compounded hormones pose an increased clinical risk compared to FDA-approved products.
Sound familiar? We covered a pre-release of the paper in February; you can read the details here.
